Tuesday, January 12, 2021 7:15:27 PM
AstraZeneca has applied for authorization for its Covid-19 vaccine in Europe and the EU pharmaceutical regulator said Tuesday it could give the go-ahead as early as Jan. 29. That´s when the European Medicines Agency´s scientific committee will meet to review analysis of the vaccine´s trial data and, if it recommends authorization, the European Commission could formally authorize AstraZeneca´s vaccine within a few days. If AstraZeneca´s Covid-19 vaccine, which was developed with Oxford University, were authorized for emergency use, it would add at least 300 million doses to the continent´s attempts to limit its deadly winter surge in Covid-19 infections. The EU has preordered 300 million doses with an option for another 100 million, and AstraZeneca has said it will manufacture up to three billion doses of its vaccine this year, which will be crucial in the effort to get doses administered in poorer countries.
A goal is a dreams deadline...what is your goal?
´¯`·.¸¸.·´¯`·.¸ ><((((((º>
`·.¸¸.·´¯`·.¸¸.·´¯`·.¸ ><((((º>
Recent AZN News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/26/2026 11:17:15 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/26/2026 11:09:57 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/26/2026 11:02:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:05:16 PM
- DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates • Business Wire • 05/22/2026 02:16:00 PM
- AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026 • Business Wire • 05/22/2026 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/18/2026 02:15:49 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/18/2026 01:42:15 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/18/2026 01:36:08 PM
- BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension • Business Wire • 05/18/2026 11:00:00 AM
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer • Business Wire • 05/16/2026 01:52:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/14/2026 11:25:03 AM
- Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial • Business Wire • 05/14/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 08:05:20 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/01/2026 02:23:42 PM
- TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer • Business Wire • 05/01/2026 01:42:00 AM
- Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca • PR Newswire (US) • 04/29/2026 11:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/29/2026 11:23:24 AM
- AstraZeneca results: Q1 2026 • Business Wire • 04/29/2026 11:00:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/28/2026 03:32:20 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/28/2026 11:31:55 AM
- BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older • Business Wire • 04/28/2026 11:00:00 AM
- SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus • Business Wire • 04/27/2026 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/27/2026 10:29:18 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/23/2026 10:10:15 AM
